Matt Callahan joined The Column Group in 2024 after completing his PhD in Chemical Biology at UC San Francisco. His thesis work in the Gestwicki Lab explored a novel mode of molecular recognition by CHIP, a ubiquitin ligase implicated in neurodegenerative disease. Matt also gained exposure to biotech company creation while at UCSF, working with the founding team of Hyku Biosciences to build their chemoproteomics platform. Prior to graduate school, Matt worked in antibody development at Genentech. He holds a B.S. in Chemical Engineering from Stanford University, where he performed research on the chemical biology of ion channels under Justin du Bois.